276 results on '"Nozzoli, Chiara"'
Search Results
2. OBITUARY- Riccardo Saccardi (20th April 1956–19th February 2024)
3. Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis
4. Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation
5. Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01
6. Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study
7. Toxoplasmosis-Associated Hemophagocytic Lymphohistiocytosis in Allogeneic Transplantation
8. The doctor who stared at schistocytes: an intriguing case of suspected thrombotic microangiopathic anemia
9. Intravesical application of platelet-rich plasma in patients with persistent haemorrhagic cystitis after hematopoietic stem cell transplantation: a single-centre preliminary experience
10. GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms
11. Effect of the COVID‐19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation
12. Diagnosis by liver stiffness measurement of sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic stem cell transplantation: results from the Italian multicentric prospective study (ELASTOVOD)
13. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
14. Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
15. Late haemophagocytic lymphohistiocytosis in a patient treated with Axicabtagene ciloleucel
16. Impact of Graft-versus-Host Disease Prophylaxis on Outcomes after Myeloablative Single-Unit Umbilical Cord Blood Transplantation
17. Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus—Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation
18. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
19. Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability
20. The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo
21. New patterns of relapse in multiple myeloma: a case of “light chain escape” in which FLC predicted relapse earlier than urine and serum immunofixation
22. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
23. Outcome and Toxicity in the Modern Era of New Drugs for Multiple Myeloma: A Reappraisal for Comparison With Future Investigational Trials
24. Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study
25. Increase in FOXP3 + Regulatory T Cells in GVHD Skin Biopsies Is Associated with Lower Disease Severity and Treatment Response
26. The Role of Bortezomib, Thalidomide and Lenalidomide in the Management of Multiple Myeloma: An Overview of Clinical and Economic Information
27. Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study
28. OS-124-YI - Diagnosis by liver stiffness measurement of sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic stem cell transplantation: results from the Italian multicentric prospective study (ELASTOVOD)
29. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients
30. On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBL06877)
31. Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience
32. Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients
33. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
34. Additional file 1: of Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
35. Percutaneous vertebroplasty and kyphoplasty in patients with multiple myeloma
36. Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation
37. The doctor who stared at schistocytes: an intriguing case of suspected thrombotic microangiopathic anemia
38. Myeloma plasma cell Multiparametric Flow Cytometry (MFC) detection in autograft products of Newly Diagnosed Multiple Myeloma (NDMM).
39. Minimal Residual Disease (MRD) ratio before and after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma.
40. Safety of rapid daratumumab infusion in relapsed and refractory multiple myeloma
41. Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
42. Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients.
43. Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes
44. Outcome of Soft-Tissue Plasmocytomas in Newly Diagnosed Multiple Myeloma Patients Treated with New Drugs
45. Late-onset hepatic veno-occlusive disease after allografting: report of two cases with atypical clinical features successfully treated with defibrotide.
46. Autologous Stem Cell Transplantation in Elderly Multiple Myeloma Patients
47. NOVEL DRUG COMBINATIONS AND DONOR LYMPHOCYTE INFUSIONS ALLOW PROLONGED DISEASE CONTROL IN MULTIPLE MYELOMA PATIENTS RELAPSING AFTER ALLOGENEIC TRANSPLANT
48. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma
49. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
50. Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.